ZOGENIX, INC. - FORM 10-K - EX-21.1 - March 1, 2021

Attached files

file filename
EX-32.2 - EX-32.2 - ZOGENIX, INC.zgnx-20201231xex322.htm
EX-32.1 - EX-32.1 - ZOGENIX, INC.zgnx-20201231xex321.htm
EX-31.2 - EX-31.2 - ZOGENIX, INC.zgnx-20201231xex312.htm
EX-31.1 - EX-31.1 - ZOGENIX, INC.zgnx-20201231xex311.htm
EX-23.1 - EX-23.1 - ZOGENIX, INC.zgnx-20201231xex231.htm
EX-10.24 - EX-10.24 - ZOGENIX, INC.zgnx-20201231exx1024.htm
10-K - 10-K - ZOGENIX, INC.zgnx-20201231.htm
Exhibit 21.1
SUBSIDIARIES OF ZOGENIX, INC.

All subsidiaries are wholly-owned, directly or indirectly, by Zogenix, Inc.


Name of SubsidiaryJurisdiction of
Formation
Modis Therapeutics, Inc.Delaware
Name of Non-U.S. SubsidiaryJurisdiction of
Formation
Zogenix Europe LimitedUnited Kingdom
Zogenix GmbHGermany
Zogenix International LimitedUnited Kingdom
Zogenix K.K.Japan
Zogenix ROI LimitedIreland
Zogenix SASFrance
Zogenix S.r.l.Italy


ZOGENIX, INC. Reports